• Rein Therapeutic’s LTI-03 inhaled dry powder synthetic peptide gets Fast Track designation for the treatment of IPF

  According to Rein Therapeutics, the FDA has granted the company’s LTI-03 inhaled dry powder synthetic peptide Fast Track designation for the treatment of idiopathic pulmonary fibrosis. The company notes that the FDA previously granted orphan… [Read more . . .]

• Bespak’s Holmes Chapel site gets Gold EcoVadis sustainability rating

  Inhalation specialist CDMO Bespak announced that its Holmes Chapel, UK site has again received a Gold EcoVadis sustainability rating, the second since Bespak was spun out from Recipharm in 2024. Earlier this year, Bespak and… [Read more . . .]

• NeOnc reports that Phase 2a trial of NEO100 intranasal perillyl alcohol in patients with brain tumors met its primary endpoint

  NeOnc Technologies announced that the Phase 2a NEO100-01 study of NEO100 intranasal perillyl alcohol in patients with Grade 3 and Grade 4 IDH1-mutant gliomas met its primary endpoint, achieving a 48.9% 6-month progression-free survival rate.… [Read more . . .]

• Scienture launches Rezenopy naloxone nasal spray in the US

  Scienture Holdings announced that the company has launched Rezenopy naloxone nasal spray in the US. Scienture acquired the US rights to Rezenopy from Summit Biosciences, a subsidiary of Kindeva Drug Delivery, in 2025. The FDA approved Summit’s… [Read more . . .]

• Zydus launches Revahale revefenacin inhalation solution for the treatment of COPD in India

  Zydus Lifesciences has announced the launch of its Revahale revefenacin inhalation solution in India. The company highlights that Revahale is the country’s first once-daily nubulized LAMA for the treatment of COPD, noting that the inhalation… [Read more . . .]

• ReCode Therapeutics names Heather Clark as its new CEO

• Harrow acquires Tyrvaya varenicline nasal spray for the treatment of dry eye disease

• Savara gets 2 new patents covering Molbreevi molgramostim inhalation solution

• MannKind says that the Phase 1b INFLO-1 trial of its nintedanib DPI met its primary endpoint

• Nasus Pharma names Brendan O’Grady as its new CEO

More news . . .